The European Medicines Agency has advised against the AstraZeneca vaccine in people with rare blood disorders

The European medicines regulator on Friday advised against the use of AstraZeneca’s COVID-19 vaccine in people with a history of rare bleeding disease and said he was studying cases of heart inflammation after inoculation of all coronavirus vaccines.

The Safety Committee of the European Medicines Agency (EMA) said in its assessment that Capillary Leak Syndrome should be added as a new side effect to the labeling of AstraZeneca vaccines.

It is a condition in which blood leaks from the smallest vessels in the muscles and cavities of the body and is characterized by swelling and low blood pressure.

Regulator started investigating these cases in April and the recommendation adds to AstraZeneca’s problems after its vaccine suffered a number of incidents, including a possible link to rare thrombus issues.

Last month, the EMA advised against the use of the second AstraZeneca vaccine for people with blood clotting problems. The agency is also expanding its research into cases of myocarditis and pericarditis following inoculation with AstraZeneca vaccine and other vaccines from Pfizer, Moderna and J&J.

EMA approval

The European Medicines Agency (EMA) stressed on Monday that maintains its support for the use of AstraZeneca “in all populations” and warns that its position “regarding this vaccine is clear”, stressing that the balance between its benefit against COVID-19 and the risk of side effects remains “positive”, after the statements of a senior official who suggested to stop distributing the formula when alternatives are available.

Marco Cavaleri, responsible for the vaccination strategy of the European regulator, was consulted by the Italian newspaper The imprint While it would not be better to ban AstraZeneca, including those over 60, to which he replied: “Yes, this is an option that many countries, like France and Germany, are considering in the fire of the increasing availability of messenger RNA vaccines. “

The EMA later said on Twiiter: “Misinformation is all the round today. Here is the situation: The benefit / risk balance of the AstraZeneca # COVID19 vaccine is positive and remains approved for all populations. “In a press release in which he points to a” miscitation “of Cavaleri, the European agency has denied that its experts have changed their position on AstraZeneca and regretted that the text of the interview “contains false information on the scientific considerations” of the regulator on the need to continue to vaccinate European citizens with this vaccine.

(With information from Reuters and AFP)

KEEP READING: